Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... USA (PRWEB) September 18, 2014 Bipartisan ... of a bill designed to stimulate development and commercialization ... is being praised by leaders of SPIE, the ... the Revitalizing American Manufacturing and Innovation (RAMI) Act, now ... bill’s authors have said they are optimistic that it ...
(Date:9/18/2014)... 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep ... Industry" and "2014 Deep Research Report on Global ... research database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... on Global and China Acetic Acid Industry" is ... China and Global Acetic Acid ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... flu is already tough, but it has become even harder in ... two antiviral drugs don,t slow it down anymore. Reporting their ... and Brigham Young move closer to understanding why not, and how ... changes. The two drugs, amantadine and rimantadine, are no longer ...
... Biosystems announced the release of its second generation of ... the company,s popular in vivo delivery product line: PEG-Liposome ... compatible for in vivo transfection of other negatively charged ... also offers custom encapsulation of target molecules into PEG-liposome ...
... Oct. 21 Sermo ( http://www.sermo.com ), the largest ... Report titled, " Physician Participation in the ESA REMS ... rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation ... the results, 83% of Hematologists/Oncologists view the ESA REMS ...
Cached Biology Technology:Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2
(Date:9/19/2014)... for the sake of fairness per se but in ... say Frans de Waal, PhD, and Sarah Brosnan, PhD, ... which is defined as a negative reaction to unequal ... , Their conclusion comes after the co-authors reviewed ... that it is the evolution of forestalling partner dissatisfaction ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2
... The American Dietetic Association has published an updated ... reviews existing programs and their value, discusses barriers to ... long-term effectiveness in helping children get and stay healthy. ... issue of the Journal of the American Dietetic ...
... In Australia, Martu hunter-gatherers light fires to expose the ... that can grow up to six feet long. These ... have reshaped Australia,s Western Desert habitats, according to Stanford ... to a group of about 800 indigenous Australians from ...
... BEER-SHEVA, ISRAEL, May 3, 2010 Ben-Gurion University ... strain which produces large amounts of a polyunsaturated fatty ... blood cholesterol level, reducing the risk for heart attacks. ... Biotechnology Lab in the Jacob Blaustein Institutes for Desert ...
Cached Biology News:ADA releases updated position paper on nutrition assistance programs for children 2Aboriginal hunting and burning increase Australia's desert biodiversity, Stanford researchers find 2Aboriginal hunting and burning increase Australia's desert biodiversity, Stanford researchers find 3Aboriginal hunting and burning increase Australia's desert biodiversity, Stanford researchers find 4Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol 2
PEG 8000, Molecular Biology Grade...
...
... (HDAC) Antibody Sampler Kit Kit Includes: ... #2062, 40 ul Histone Deacetylase 3 (HDAC3) ... 4 (HDAC4) Antibody, Catalog #2072, 40 ul ... 40 ul Histone Deacetylase 6 (HDAC6) Antibody, ...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Biology Products: